Owlet, Inc.
NYSE:OWLTMedical - Devices
+$0.46 today
- Market cap
- $107.24M
- Beta
- 1.86
- P/E (TTM)
- -0.4
- EPS (TTM)
- -$12.67
Volume 0.64M
Average 0.24M
OWLT Gross Margin
Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.
Owlet, Inc.NYSE: OWLT
Gross Margin · Q1 FY2026 · quarter ended Mar 2026
Gross margin widens to 54.5%
Gross margin was 54.5% in Q1 FY2026, up 0.8 pp from a year earlier. On a trailing-twelve-month basis it was 50.9%, down 1.4 pp year over year. Over 3 fiscal years it widened by 17.0 pp.
Context
- Gross margin widened in 3 of the last 3 fiscal years.
- FY2025 was the highest level in the 4 fiscal years shown.
Sources:Income StatementText generated from reported figures; not investment advice.
Gross Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- 50.6%
- Year-over-year change
- +0.3pp
| Period | Period end | Gross Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 50.6% | +0.3pp |
| FY2024 | 2024-12-31 | 50.4% | +8.5pp |
| FY2023 | 2023-12-31 | 41.8% | +8.1pp |
| FY2022 | 2022-12-31 | 33.7% | -12.5pp |
| FY2021 | 2021-12-31 | 46.2% | — |
Gross Margin vs competitors
How OWLT compares with its peers on the latest reported figures
- OWLT's LTM Mar 2026 gross margin of 50.9% is the 3rd highest of the 8 companies compared; the peer median is 28.3%.
- Its year-over-year change of -1.4 pp is the 4th highest of 8, against a peer median of -2.1 pp.
- Over three fiscal years its change of +17.0 pp compares with a peer median of -7.3 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Mar 2026 | 80.7% | -0.2 pp | -7.3 pp | |
| LTM Mar 2026 | 58.6% | -4.1 pp | -7.8 pp | |
| LTM Mar 2026 | 50.9% | -1.4 pp | +17.0 pp | |
| LTM Mar 2026 | 45.3% | -2.1 pp | -10.0 pp | |
AVRAnteris Technologies Global Corp. | LTM Mar 2026 | 28.3% | -24.8 pp | -25.9 pp |
| LTM Mar 2026 | 12.4% | +6.3 pp | +72.5 pp | |
| LTM Mar 2026 | -40.0% | +27.6 pp | +798.4 pp | |
| LTM Mar 2026 | -2105.7% | -548.4 pp | +0.0 pp | |
| FY2025 | — | — | — | |
ELTXElicio Therapeutics, Inc. | FY2025 | — | — | — |
| Peer median (excluding OWLT) | 28.3% | -2.1 pp | -7.3 pp | |
Competitors are the stored peer set for OWLT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 75.84M | 69.2M | 54.01M | 78.06M | 105.71M |
| Cost of Revenue | 40.78M | 45.89M | 31.42M | 38.75M | 52.18M |
| Gross Profit | 35.06M | 23.31M | 22.59M | 39.31M | 53.53M |
| Gross Margin | 46.2% | 33.7% | 41.8% | 50.4% | 50.6% |
| Research & Development | 21.43M | 27.9M | 10.35M | 9.8M | 14.08M |
| Selling, General & Admin | 69.42M | 80.04M | 40.87M | 49.73M | 47.72M |
| Operating Expenses | 90.85M | 107.93M | 51.22M | 59.53M | 61.79M |
| Depreciation & Amortization | 1.13M | 2.67M | 2.21M | 1.38M | 590K |
| EBITDA | (42.71M) | (75.53M) | (27.49M) | (9.47M) | (35.64M) |
| EBITDA Margin | -56.3% | -109.1% | -50.9% | -12.1% | -33.7% |
| Operating Income | (55.79M) | (84.62M) | (28.63M) | (20.22M) | (8.26M) |
| Operating Margin | -73.6% | -122.3% | -53.0% | -25.9% | -7.8% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 27.83M | 1.1M | 3.19M | 1.63M | 3.42M |
| Other Income / Expenses | (15.88M) | 5.31M | (4.26M) | 7.74M | (31.39M) |
| Income Before Tax | (71.67M) | (79.31M) | (32.89M) | (12.48M) | (39.65M) |
| Pre-Tax Margin | -94.5% | -114.6% | -60.9% | -16.0% | -37.5% |
| Income Tax Expense | 31K | 29K | 10K | 54K | 28K |
| Net Income | (71.7M) | (79.34M) | (32.9M) | (12.54M) | (39.68M) |
| Net Margin | -94.5% | -114.6% | -60.9% | -16.1% | -37.5% |
| EPS (Basic) | (12.47) | (9.97) | (4.53) | (0.83) | (2.24) |
| EPS (Diluted) | (12.47) | (9.97) | (4.53) | (0.83) | (2.24) |
| Weighted Avg Shares | 7.87M | 7.95M | 8.28M | 15.11M | 562.5M |
| Weighted Avg Shares (Diluted) | 7.87M | 7.95M | 8.28M | 15.11M | 562.5M |
Owlet, Inc.
NYSE:OWLT
Intrinsic Alpha fair value
Locked
Current Price
$3.67
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.